...in ALS. Denali Therapeutics Inc. gained the rights to Yuan's RIPK1 program when it acquired Incro Pharmaceuticals Corp....

...the deals announced on Aug. 25 add three first-in-class pipeline programs from Genentech Inc. , Incro Pharmaceuticals Corp....

...rights to the program from Harvard University (Cambridge, Mass.). Denali declined to disclose financial terms. Incro Pharmaceuticals Corp....

...future trials in AD and ALS. The company gained the program through its acquisition of Incro Pharmaceuticals...